The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine.

EndNote Style
Original Article
The role of malondialdehyde in the evaluation of the treatment response in acute pulmonary thromboembolism
Aims: To facilitate the early diagnosis of the related patient group by investigating the level of Malondialdehyde (MDA) in high-risk pulmonary thromboembolism (PTE). In addition, it was aimed to see the effect of treatment after acute PTE on oxidative stress and to evaluate whether it is associated with the development of chronic thrombus.
Methods: This study was conducted prospectively in 44 patients diagnosed with PTE in single-center. At the time of diagnosis, after 6 months of follow-up and treatment, the MDA levels of the patients were evaluated together with the controlled tests.
Results: MDA level was found to be a determinant in the estimation of high-risk PTE. In addition, MDA level was found to be higher at the time of diagnosis and after treatment in patients with chronic thromboembolism.
Conclusion: MDA level is a guiding parameter in high-risk PTE. In addition, the continuation of oxidative stress in the case of chronic thrombus may be important in the remodeling of the precapillary pulmonary artery.

1. Cohen A, Jeyaindran S, Kim JY, et al. Treating pulmonary embolism in PacificAsia with direct oral anticoagulants. Thromb Res. 2015; 136(2):196-207.
2. Rosendaal FR. Risk factors for venous thrombotic disease. ThrombHaemost. 1999;82(2):610-619.
3. Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics,management, and outcomes of patients diagnosed with acutepulmonary embolism in the emergency department: initial report ofEMPEROR (Multicenter Emergency Medicine Pulmonary Embolism inthe Real World Registry). J Am Coll Cardiol. 2011;57(6):700-706.
4. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolutionof thromboemboli in patients with acute pulmonary embolism: asystematic review. Chest. 2006;129(1):192-197.
5. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basicmechanisms of chronic thromboembolic pulmonary hypertension: acurrent understanding. Eur Respir J. 2013;41(2):462-468.
6. Karabulut H, Gülay MŞ. Serbest radikaller. MAKÜ Sağ Bil Enst Derg.2016;4(1):50-59.
7. Botham KM, Moyes PA. Fizyolojik öneme sahip lipidler. In: GrannerRK, Mayes DK, Rodwell RA, Murray VW, eds. Harper’ın biyokimyası.Barış Kitabevi, 1996.
8. Mühl D, Füredi R, Cristofari J, et al. Evaluation of oxidative stress inthe thrombolysis of pulmonary embolism. J Thromb Thrombolysis.2006;22(3):221-228.
9. Tapson VF, Weinberg AS. Overview of management of intermediate- andhigh-risk pulmonary embolism. Crit Care Clin. 2020;36(3):449-463.
10. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol.2014;12(8):464-474.
11. Ageno W, Haas S, Weitz JI, et al. Characteristics and management ofpatients with venous thromboembolism: the GARFIELD-VTE registry.Thromb Haemost. 2019;119(2):319-327.
12. Yoshikawa Y, Yamashita Y, Morimoto T, et al. Sex differences in clinicalcharacteristics and outcomes of patients with venous thromboembolism- from the COMMAND VTE registry. Circ J. 2019;83(7):1581-1589.
13. White RH. The epidemiology of venous thromboembolism. Circulation.2003;107:(1)4-8.
14. Özsu S, Özlü T, Bülbül Y. Ulusal verilerle pulmoner tromboemboli.Tuberk Toraks. 2009;57(4):466-482.
15. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponinsin acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427-433.
16. Lankeit M, Jiménez D, Kostrubiec M, et al. Predictive value of thehigh-sensitivity troponin t assay and the simplified pulmonaryembolism severity index in hemodynamically stable patients withacute pulmonary embolism: a prospective validation study. Circulation.2011;124(24):2716-2724.
17. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brainnatriuretic peptide in acute pulmonary embolism. Circulation.2003;107(20):2545-2547.
18. Chen YL, Wright C, Pietropaoli AP, et al. Right ventricular dysfunctionis superior and sufficient for risk stratification by a pulmonaryembolism response team. J Thromb Thrombolysis. 2020;49(1):34-41.
19. Bulkley GB. The role of oxygen free radicals in human diseaseprocesses. Surgery. 1983;94(3):407-411.
20. Pradeep H, Diya JB, Shashikumar S, Rajanikant GK. Oxidative stress--assassin behind the ischemic stroke. Folia Neuropathol. 2012;50(3):219-230.
21. Özkul A, Akyol A, Yenisey C, Arpacı E, Kıylıoğlu N, TataroğluC. Oxidative stress in acute ischemic stroke. J Clin Neurosci.2007;14(11):1062-1066.
22. Aykal G, Güven R, Yeğin A, Ellidağ HY, Bayindir A, Yilmaz N. Thediagnostic value of oxidative/antioxidative balance parameters invenous thromboembolism. Clin Lab. 2015;61(7):769-775.
23. Batmaz E, Edis Çakır E, Eskiocak S, Hatipoğlu ON, Kaya S. Thediagnostic value of oxidative stress products in pulmonary embolism.Turk Thorac J. 2011;12(3):100-104.
24. Halıcı B, Sarınç Ulaşlı S, Günay E, et al. Assessment of inflammatorybiomarkers and oxidative stress in pulmonary thromboembolism:follow-up results. Inflammation. 2014;37(4):1186-1190.
25. Reis GS, Augusto VS, Silveira AP, et al. Oxidative-stress biomarkers inpatients with pulmonary hypertension. Pulm Circ. 2013;3(4):856-861.
26. Smukowska-Gorynia A, Rzymski P, Marcinkowska J, et al. Prognosticvalue of oxidative stress markers in patients with pulmonary arterialor chronic thromboembolic pulmonary hypertension. Oxid Med CellLongev. 2019;3795320.
27. Morris TA. Why acute pulmonary embolism becomes chronicthromboembolic pulmonary hypertension: clinical and geneticinsights. Curr Opin Pulm Med. 2013;19(5):422-429.
Volume 1, Issue 4, 2023
Page : 86-90